6mkd: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
<StructureSection load='6mkd' size='340' side='right'caption='[[6mkd]], [[Resolution|resolution]] 3.20Å' scene=''> | <StructureSection load='6mkd' size='340' side='right'caption='[[6mkd]], [[Resolution|resolution]] 3.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6mkd]] is a 4 chain structure with sequence from [ | <table><tr><td colspan='2'>[[6mkd]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MKD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6MKD FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.2Å</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6mkd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6mkd OCA], [https://pdbe.org/6mkd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6mkd RCSB], [https://www.ebi.ac.uk/pdbsum/6mkd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6mkd ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/HA2B_MOUSE HA2B_MOUSE] | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 19: | Line 18: | ||
</div> | </div> | ||
<div class="pdbe-citations 6mkd" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 6mkd" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[MHC 3D structures|MHC 3D structures]] | |||
*[[MHC II 3D structures|MHC II 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
Line 24: | Line 27: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: | [[Category: Mus musculus]] | ||
[[Category: Blevins SJ]] | |||
[[Category: Blevins | [[Category: Huseby ES]] | ||
[[Category: Huseby | [[Category: Stadinski BD]] | ||
[[Category: Stadinski | |||
Latest revision as of 09:33, 11 October 2023
4699 TCR bound to I-Ab Padi44699 TCR bound to I-Ab Padi4
Structural highlights
FunctionPublication Abstract from PubMedThe neonatal thymus generates Foxp3(+) regulatory T (tTreg) cells that are critical in controlling immune homeostasis and preventing multiorgan autoimmunity. The role of antigen specificity on neonatal tTreg cell selection is unresolved. Here we identify 17 self-peptides recognized by neonatal tTreg cells, and reveal ligand specificity patterns that include self-antigens presented in an age- and inflammation-dependent manner. Fate-mapping studies of neonatal peptidyl arginine deiminase type IV (Padi4)-specific thymocytes reveal disparate fate choices. Neonatal thymocytes expressing T cell receptors that engage IA(b)-Padi4 with moderate dwell times within a conventional docking orientation are exported as tTreg cells. In contrast, Padi4-specific T cell receptors with short dwell times are expressed on CD4(+) T cells, while long dwell times induce negative selection. Temporally, Padi4-specific thymocytes are subject to a developmental stage-specific change in negative selection, which precludes tTreg cell development. Thus, a temporal switch in negative selection and ligand binding kinetics constrains the neonatal tTreg selection window. A temporal thymic selection switch and ligand binding kinetics constrain neonatal Foxp3(+) Treg cell development.,Stadinski BD, Blevins SJ, Spidale NA, Duke BR, Huseby PG, Stern LJ, Huseby ES Nat Immunol. 2019 Jun 17. pii: 10.1038/s41590-019-0414-1. doi:, 10.1038/s41590-019-0414-1. PMID:31209405[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|